Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program

Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program

Purpose: Among metastatic breast cancer (MBC) patients, those with a triple-negative breast cancer phenotype (mTNBC) have the worst prognosis, but the benefit of chemotherapy beyond second line on outcome remains uncertain. The purpose of this study was to identify predictive factors of outcome afte...

Full description

Bibliographic Details
Main Authors: Luc Cabel, Matthieu Carton, Barbara Pistilli, Florence Dalenc, Laurence Vanlemnens, Christelle Levy, William Jacot, Michel Debled, Agnes Loeb, Audrey Hennequin, Thibault De la Motte Rouge, Lilian Laborde, Carine Laurent, E. Chamorey, Damien Parent, Thierry Petit, Marie-Ange Mouret-Reynier, Mario Campone, Geneviève Perrocheau, Claire Labreveux, Thomas Bachelot, Mathieu Robain, Florence Lerebours
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:Breast
Subjects:
Metastatic breast cancer
Prognostic factors
Real-life
Heavily pretreated
Chemotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S096097762100014X

Internet

http://www.sciencedirect.com/science/article/pii/S096097762100014X

Similar Items